Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes

Leuk Lymphoma. 2017 Sep;58(9):1-4. doi: 10.1080/10428194.2017.1287360. Epub 2017 Feb 13.

Affiliations

¹ a Department of Internal Medicine III , University Hospital of Ulm , Ulm , Germany.
² b Medical Prognosis Institute (MPI) , Hørsholm , Denmark.
³ c Department of Internal Medicine I , University of Freiburg Faculty of Medicine , Freiburg , Germany.

PMID: 28278722
DOI: 10.1080/10428194.2017.1287360

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antimetabolites, Antineoplastic / administration & dosage
Antimetabolites, Antineoplastic / adverse effects
Antimetabolites, Antineoplastic / therapeutic use*
Azacitidine / administration & dosage
Azacitidine / adverse effects
Azacitidine / analogs & derivatives*
Azacitidine / therapeutic use
Biomarkers, Tumor*
Decitabine
Gene Expression Profiling
Gene Expression Regulation, Leukemic*
Genes, Tumor Suppressor
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / pathology
Transcriptome*
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Biomarkers, Tumor
Decitabine
Azacitidine